Intra-Cellular [ITCI] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

Intra-Cellular Therapies Inc.

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Intra-Cellular Therapies Inc. wins in 4 metrics, Haleon Plc - ADR wins in 14 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Intra-Cellular Therapies Inc. Haleon Plc - ADR Better
P/E Ratio (TTM) -183.15 18.72 Haleon Plc - ADR
Price-to-Book Ratio 12.20 1.88 Haleon Plc - ADR
Debt-to-Equity Ratio 1.48 52.37 Intra-Cellular Therapies Inc.
PEG Ratio 507.19 15.42 Haleon Plc - ADR
EV/EBITDA -112.19 33.08 Haleon Plc - ADR
Profit Margin (TTM) -10.97% 15.11% Haleon Plc - ADR
Operating Margin (TTM) -14.66% 23.17% Haleon Plc - ADR
EBITDA Margin (TTM) N/A 23.17% N/A
Return on Equity -8.58% 10.27% Haleon Plc - ADR
Return on Assets (TTM) -6.96% 4.67% Haleon Plc - ADR
Free Cash Flow (TTM) $-73.50M $2.22B Haleon Plc - ADR
Dividend Yield N/A 1.63% N/A
1-Year Return 92.68% -16.01% Intra-Cellular Therapies Inc.
Price-to-Sales Ratio (TTM) 20.63 3.78 Haleon Plc - ADR
Enterprise Value $13.04B $122.54B Haleon Plc - ADR
EV/Revenue Ratio 19.15 8.23 Haleon Plc - ADR
Gross Profit Margin (TTM) 89.76% 55.38% Intra-Cellular Therapies Inc.
Revenue per Share (TTM) $7 $2 Intra-Cellular Therapies Inc.
Earnings per Share (Diluted) $-0.73 $0.50 Haleon Plc - ADR
Beta (Stock Volatility) 0.46 0.33 Haleon Plc - ADR
Short % of Float N/A 0.43% N/A

Intra-Cellular Therapies Inc. vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

ITCI
HLN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Intra-Cellular Therapies Inc.0.00%N/AN/AN/AN/AN/A
Haleon Plc - ADR-0.66%2.02%1.23%-13.29%-7.73%-9.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Intra-Cellular Therapies Inc.92.68%104.13%700.67%449.92%632.61%632.61%
Haleon Plc - ADR-16.01%8.43%23.21%23.21%23.21%23.21%

Performance & Financial Health Analysis: Intra-Cellular Therapies Inc. vs Haleon Plc - ADR

MetricITCIHLN
Market Information
Market Cap i$14.05B$42.40B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i2,749,3686,594,249
90 Day Avg. Volume i2,309,5097,985,230
Last Close$131.87$9.07
52 Week Range$64.09 - $131.98$8.65 - $11.28
% from 52W High-0.08%-19.59%
All-Time High$131.98 (Mar 31, 2025)$11.42 (Jun 02, 2025)
% from All-Time High-0.08%-20.58%
Growth Metrics
Quarterly Revenue Growth0.51%0.01%
Quarterly Earnings Growth0.51%0.86%
Financial Health
Profit Margin (TTM) i-0.11%0.15%
Operating Margin (TTM) i-0.15%0.23%
Return on Equity (TTM) i-0.09%0.10%
Debt to Equity (MRQ) i1.4852.37
Cash & Liquidity
Book Value per Share (MRQ)$10.81$4.99
Cash per Share (MRQ)$9.42$0.15
Operating Cash Flow (TTM) i$-73,177,000$3.56B
Levered Free Cash Flow (TTM) i$-63,549,624$1.89B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: Intra-Cellular Therapies Inc. vs Haleon Plc - ADR

MetricITCI (May 17, 2025)HLN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-183.1518.72
Forward P/E i507.1915.42
PEG Ratio i507.1915.42
Price to Sales (TTM) i20.633.78
Price to Book (MRQ) i12.201.88
Market Capitalization
Market Capitalization i$14.05B$42.40B
Enterprise Value i$13.04B$122.54B
Enterprise Value Metrics
Enterprise to Revenue i19.158.23
Enterprise to EBITDA i-112.1933.08
Risk & Other Metrics
Beta i0.460.33
Book Value per Share (MRQ) i$10.81$4.99

Financial Statements Comparison: Intra-Cellular Therapies Inc. vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricITCI (2024)HLN (2025)
Revenue/Sales i680.50M11.03B
Cost of Goods Sold i56.96M3.95B
COGS % of Revenue i8.4%35.8%
Gross Profit i623.54M7.08B
Gross Margin i91.6%64.2%
Research & Development i236.12M316.00M
Operating Income (EBIT) i-116.72M2.41B
Operating Margin i-17.2%21.9%
EBITDA i-116.21M2.81B
EBITDA Margin i-17.1%25.5%
Pre-Tax Income i-74.20M2.15B
Pre-Tax Income % of Revenue i-10.9%19.5%
Income Tax i473,000472.00M
Income Tax % of Revenue i0.1%4.3%
Net Income (Profit) i-74.68M1.68B
Profit Margin i-11.0%15.2%

Balance Sheet & Liquidity Metrics

MetricITCI (2024)HLN (2025)
Cash & Equivalents i306.95M1.26B
Total Current Assets i1.31B4.55B
Total Current Assets % of Revenue i192.1%41.3%
Total Current Liabilities i205.70M4.93B
Total Current Liabilities % of Revenue i30.2%44.7%
Long-Term Debt i12.75M7.75B
Long-Term Debt % of Revenue i1.9%70.2%
Total Shareholders Equity i1.15B16.48B
Retained Earnings i-1.69B27.85B
Retained Earnings % of Revenue i-248.6%252.5%
Property, Plant & Equipment i14.90M1.00M

Cash Flow Statement Comparison

MetricITCI (2024)HLN (2025)
Operating Cash Flow i-63.27M2.19B
Operating Cash Flow % of Revenue i-9.3%19.8%
Capital Expenditures i-322,000-322.00M
Free Cash Flow i-73.50M2.22B
FCF Margin i-10.8%20.1%
Debt Repayment iN/A-1.35B
Common Stock Repurchase iN/A-654.00M

Short Interest & Institutional Ownership Analysis

MetricITCIHLN
Shares Short iN/A19.28M
Short Ratio iN/A2.14
Short % of Float iN/A0.43%
Shares Outstanding i106.24M8.91B
Float Shares i104.82M8.86B
% Held by Insiders i2.48%0.01%
% Held by Institutions i96.45%12.74%
% Held by Public i1.07%87.25%

Dividend Analysis & Yield Comparison: Intra-Cellular Therapies Inc. vs Haleon Plc - ADR

MetricITCIHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025